Expert panel issues consensus guidance on pediatric oral minoxidil

An international Delphi-based consensus statement developed recommendations for off-label use of low-dose oral minoxidil (LDOM) in pediatric hair disorders, addressing patient selection, dosing, safety, and monitoring. Of 127 items reviewed by 49-50 experts across three survey rounds, 84 reached consensus, including weight-based dosing regimens, dosage escalation and reassessment intervals, contraindications (pericardial effusion/tamponade, pheochromocytoma), and support for long-term and combination therapy. The statement notes that routine baseline testing and blood pressure monitoring were not deemed universally necessary in low-risk patients, per the experts surveyed.

Most relevant for: Clinicians managing hair loss disorders in pediatric patients under age 12, including those considering off-label oral minoxidil therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.